
    
      The primary objective of this study is to compare the effects of gluten treated with ALV003
      vs placebo:

        -  The clinical response by symptom measurement before and after oral challenge

        -  The immune response measured by ELISPOT testing and serology The secondary objective of
           the study is to

        -  Describe the immunotoxic epitope profile of gluten digests with ALV003 compared with
           placebo
    
  